Carisma Therapeutics, Inc. CARM

NAS: CARM | ISIN: US14216R1014   16:01
1,351 USD (-3,53%)
(-3,53%)   16:01

16 mei 2024 · Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte · Persbericht

9 mei 2024 · Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

8 mei 2024 · Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 · Persbericht

6 mei 2024 · Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference · Persbericht

2 mei 2024 · Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer · Persbericht

24 april 2024 · Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting · Persbericht

22 april 2024 · Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting · Persbericht

3 april 2024 · Carisma Therapeutics to Present at Upcoming Conferences · Persbericht

1 april 2024 · Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

1 april 2024 · Carisma Therapeutics Announces Changes to its Board of Directors · Persbericht

21 maart 2024 · Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting · Persbericht

28 februari 2024 · Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference · Persbericht

21 december 2023 · Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

14 december 2023 · First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration · Persbericht

9 november 2023 · Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

31 oktober 2023 · Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC · Persbericht

25 oktober 2023 · Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023 · Persbericht

5 september 2023 · Carisma Therapeutics to Present at Upcoming Investor Conferences · Persbericht

1 september 2023 · Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit · Persbericht

24 augustus 2023 · Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 · Persbericht

Mijn selecties